Glioblastoma: An aggressive brain cancerdepare
Glioblastoma multiforme (GBM) is an aggressive and life-threatening form of brain cancer. Although brain cancers as a whole are relatively uncommon, GBM are the most common type of malignant brain tumour in adults. The most common symptoms that appear are relatively innocuous recurring headaches, difficulty thinking and speaking, blurry vision and unusual changes in mood or personality making early detection a challenge. Patients often display advanced disease at the time of diagnosis reducing the therapeutic window of opportunity.
Treatments including surgery, radiation and chemotherapy are available but the disease remains incurable and devastating1.
If cancer is considered the emperor of all maladies, then it is fair to say that cancer stem cells (CSCs) are the seeds that spread this evil. Cells within highly aggressive tumours, such as GBM, display poorly differentiated characteristics including high expression of genes enriched in pluripotent embryonic stem cells (ESCs) posing molecular parallels between the stem cell pheno- type, induced pluripotency, and cancer. In GBM, transcriptome analysis of clinical samples identified distinct subtypes based on molecular signatures (i.e. mesenchymal, classical, and proneural) with the mesenchymal subtype, thought to be the most aggressive, sharing a high-degree of similarity with stem cells at the transcriptome and epigenetic level2.
Moreover, single-cell analysis shows GBM cells exist in at least four different cellular states and can transition dynamically between molecular subtypes depending on cell-intrinsic and extrinsic factors3. This high-degree of transcriptional and epigenetic adaptability is thought to influence the emergence of therapy-resistant GBM cell sub-populations and plays a pivotal role in establishing intra-tumour heterogeneity4.
Identifying novel and creative ways to eradicate the apical tumour-progenitor cell (i.e. CSC) and block these cellular transitions will more effectively treat deadly tumours, such as GBM, and prevent recurrence5.
In recent years we have come to the paradigm-shifting realisation that non- stem-like cancer cells can acquired stem-like traits in very dynamic fashion in response to multiple stimuli, including those designed to get rid of the tumour itself10. This ability to switch phenotypes, commonly referred to as plasticity, is a key feature that allows neoplastic cells to adapt and maintain tumour growth. Plasticity requires extensive transcriptional changes and is driven, in large part, by pluripotency factors (i.e. Oct4, Sox2, Klf4, and c-Myc). A key component of these transcriptional changes are epigenetic alterations including nucleosome re-positioning, re-distribution of DNA and histone modifications, and expression of non-coding RNAs.
Over the last decade our lab has been focused on understanding what drives the de-differentiation of GBM cells to their tumour-propagating state with the goal of identifying and exploiting tumour cell vulnerabilities6-10. We were at the forefront of identifying a role for pluripotency factors in controlling the tumour-propagating phenotype of GBM stem-like cells9.
Our work has uncovered a molecular circuit in which pluripotency factors Oct4 and Sox2 drive GBM stem cell transitions and tumour propagation, in part, by repressing non-coding RNAS (i.e. miRNAs) that regulate two distinct epigenetic mechanisms: (i) changes in chromatin architecture through the action of HMGA110, and (ii) DNMT-dependent DNA methylation events9.
Importantly, we show that normalisation of epigenetic networks by reconstituting these non-coding RNAs inhibits the tumour propagation capacity of GBM stem cells with curative effects in pre-clinical GBM xenograft models 8.
Non-coding RNAs (ncRNAs), in particular microRNAs (miRNAs), are emerging as critical regulators of cell fate and oncogenesis. miRNAs are a class of endogenous double-stranded RNAs 19-22 nucleotides long that repress activity of complementary messenger RNAs (mRNAs) selectively by targeting mRNA for degradation usually via complementary 3-UTR seed sequences.
Cutting-edge advances in nanocarrier technology now allows us to accommodate payloads consisting of multiple ncRNA types that can be optimised for delivery to specific cell types, providing a high level of control to minimise off-target effects. We show that nano-carriers can be used to effectively deliver miRNA mimics and/or inhibitors (i.e. antagomirs) to regulate the GBM stem cell phenotype in vivo and this technology can be combined with other treatment modalities (e.g. radiation) to create a window of opportunity that sensitises tumour cells to chemo/radiation for long-term disease management7,8.
Our work with miRNAs highlights that understanding these context-specific, multi-dimensional interactions can lead to a sophisticated, mechanism-based, rational approach to designing molecular cancer therapeutics.
One feature of miRNAs, the advantages of which are frequently overlooked, is the ability of one miRNA to target multiple mRNA transcripts. Integrating next-generation sequencing (NGS) data and bioinformatics can allows to select one miRNA to target multiple parallel oncogenic pathways using a single agent. This rational top down approach to using miRNAs as therapeutic tools has the potential to significantly advance the development of next generation molecular therapeutics. It shouldnt be surprising if in the near future we see next-generation nanocarriers with improved stability and blood-brain-barrier (BBB) penetration being tested as systemic delivery vehicles for miRNAs to GBM.
We can also expect to see approaches take advantage of localised, transient disruption of the BBB to permeabilise regions in the brain to enhance uptake of nanoparticles and specifically target tumour regions.
Breakthroughs in the field of cranioplasty surgery now allows for next-generation implants harbouring technology that are being developed for ambulatory convection-enhanced delivery (CED) uses that will perfectly compliment these nanocarrier-based drug delivery applications. As our understanding of miRNA biology in cancer grows and new technologies for efficient in vivo delivery of these agents expands we can expect to see an exponential grow in innovative molecular therapeutics for GBM.
References
Please note: This is a commercial profile
2019. This work is licensed underCC-BY-NC-ND.
Editor's Recommended Articles
See the original post here:
miRNAs in brain cancer therapy Mighty things from small beginnings grow - Open Access Government
- Secret to eternal youth? John Cleese extols virtues of stem cell treatment - The Guardian - April 26th, 2024
- Cabinet approves two bills on regenerative medicine - - April 26th, 2024
- Parental Fury After Stem Cell Bank Ruins Thousands of Samples in Singapore - Bloomberg - April 24th, 2024
- Pressure in the womb may influence facial development - Phys.org - April 24th, 2024
- Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis - Nature.com - April 24th, 2024
- Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform - FiercePharma - April 19th, 2024
- The Stem Cells Market expected to grow at the value of USD 28.1 Billion by 2030 with a 10.48% CAGR. - WhaTech - April 19th, 2024
- Scientists produce in vitro model of cell differentiation during early facial development - Phys.org - April 19th, 2024
- Somite: AI-Based Stem Cell Therapy Company Closes $5.3 Million In Funding - Pulse 2.0 - April 19th, 2024
- Paralyzed man who can walk again shows potential benefit of stem cell therapy - ABC News - April 5th, 2024
- Stem Cells Market Innovations Investigated by Industry Overview and Global Forecast - WhaTech - April 5th, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - University of Wisconsin-Madison - April 1st, 2024
- The PTM profiling of CTCF reveals the regulation of 3D chromatin structure by O-GlcNAcylation - Nature.com - April 1st, 2024
- Signatures of Autofluorescence Used To Study Stem Cells Aging in the Brain - Technology Networks - March 30th, 2024
- Two decades of embryonic stem cells: a historical overview - March 28th, 2024
- Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats - The Malaysian Reserve - March 26th, 2024
- Unlocking the mysteries of early human development through blastoid models - News-Medical.Net - March 24th, 2024
- Unlocking the Secrets of Aging: Researchers Reveal Key to Intestinal Balance - SciTechDaily - March 17th, 2024
- Human stem-cell-based therapy for Parkinson's disease proven safe PET - BioNews - March 13th, 2024
- Exploring the inner workings of stem cells: When location changes the message - Phys.org - March 9th, 2024
- Confronting IVF: Human Embryos Are Persons With a Right to Life - Walter Bradley Center for Natural and Artificial Intelligence - March 7th, 2024
- When Location Changes the Message - UConn Today - University of Connecticut - March 7th, 2024
- Distinct pathways drive anterior hypoblast specification in the implanting human embryo - Nature.com - March 6th, 2024
- In light of the Alabama court ruling, a look at the science of IVF : Short Wave - NPR - March 3rd, 2024
- The weird way Alabamas embryo ruling takes on artificial wombs - MIT Technology Review - February 25th, 2024
- Alabama's biggest hospital to suspend transfer of embryos after court ruling - ABC News - February 24th, 2024
- Stem Cells: FAQs Answered for Patients and Caregivers - Corporate Wellness Magazine - February 22nd, 2024
- Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells - Business Wire - February 22nd, 2024
- Breakthrough Stem Cell Treatments for Stroke Recovery: What You Need to Know - Medical Tourism Magazine - February 20th, 2024
- Global Cell Isolation Market Size To Worth USD 13.4 Billion By 2033 | CAGR of 12.5% - Yahoo Finance - February 20th, 2024
- The Mechanism of Positional Cues in Embryonic Development and Signaling Molecules in Cell Fate - Medriva - February 18th, 2024
- Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review - Cureus - February 5th, 2024
- CRISPR/Cas9-mediated deletion of a GA-repeat in human GPM6B leads to disruption of neural cell differentiation from ... - Nature.com - January 29th, 2024
- Global Human Embryonic Stem Cell Market Analysis 2024-2034: A Deep Dive into Applications, End-users, and ... - GlobeNewswire - January 26th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News - January 14th, 2024
- Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com - January 12th, 2024
- How Stem Cell Embryo Models Won Method of the Year - Technology Networks - January 12th, 2024
- Changing the public perception of human embryology - ESHRE - January 11th, 2024
- How the Human Body Regenerates New Cells Every Year - Laughing Squid - January 4th, 2024
- Lab-grown models of embryos increasingly resemble the real thing | Mint - Mint - January 4th, 2024
- Singapore should ban reproductive applications of synthetic human embryos - BioEdge - January 4th, 2024
- Machine learning-based estimation of spatial gene expression pattern during ESC-derived retinal organoid ... - Nature.com - December 21st, 2023
- The development of embryos may be less shaped by genes than we thought - New Scientist - December 21st, 2023
- Embryonic stem cell - Wikipedia - December 13th, 2023
- Researchers discover a mechanism that controls the identity of stem cells - Phys.org - December 9th, 2023
- 'Fascinating and completely unexpected': Tiny robots fix neurons - FierceBiotech - December 5th, 2023
- Establishment and characterization of matched immortalized human ... - Nature.com - December 5th, 2023
- Proteomic insights into the associations between obesity, lifestyle ... - BMC Medicine - December 5th, 2023
- New therapy can treat rare and hereditary diseases - ScienceNorway - December 5th, 2023
- Scientists Still Can't Be Trusted on Gene Editing - Progressive.org - December 5th, 2023
- Harvard Apparatus Regenerative Technology and Renowned ... - Yahoo Finance - December 5th, 2023
- 4.4 Million Funding Injection Fuels World-Class Bioscience Research Programme - India Education Diary - December 3rd, 2023
- A two-kinesin mechanism controls neurogenesis in the developing ... - Nature.com - December 3rd, 2023
- What happens when nature and cities collide - CNN - December 3rd, 2023
- Pro-Life This Week: December 1, 2023 | ALL - All.org - December 3rd, 2023
- A look at the international race to create human eggs and sperm in ... - NPR - December 1st, 2023
- Synthetic genetic circuits to uncover the OCT4 trajectories of ... - Science - December 1st, 2023
- Why the Novo Nordisk Foundation is betting big on stem cells - pharmaphorum - November 29th, 2023
- Charity Watchlist Helps Donors Ensure Their Year-End Gifts Don't ... - All.org - November 29th, 2023
- A green glowing monkey has been created in China. What were the ... - Genetic Literacy Project - November 29th, 2023
- Fetal Bovine Serum Market to reach USD 1.26 Bn by 2029, emerging at a CAGR of 5.3 percent according to a ne... - WhaTech Technology and Markets News - November 29th, 2023
- Implications of Gene Therapy in Dentistry and Periodontics: A ... - Cureus - November 27th, 2023
- Study shows how to treat hereditary, rare diseases - ETHealthWorld - November 27th, 2023
- Drugs identified that may reverse brain fog caused by COVID-19 - New Atlas - November 27th, 2023
- The genes that made us truly human may also make us ill - BBC.com - November 25th, 2023
- Therapy to treat rare, hereditary diseases: Study - Hindustan Times - November 25th, 2023
- How the growth of a giant single cell is intertwined with daily self-rhythms - Phys.org - November 25th, 2023
- On this day: Mahmoud Abbas becomes leader of Fatah in 2004 - In-Cyprus - November 25th, 2023
- Evaluation of A-ring hydroxymethylene-amino- triterpenoids as ... - Nature.com - November 25th, 2023
- Disruption of the autism gene and chromatin regulator KDM5A alters ... - Science - November 23rd, 2023
- Scientists Created a Monkey With Two Different Sets of DNA - Smithsonian Magazine - November 23rd, 2023
- Genomic tug of war could boost cancer therapy - Science Daily - November 23rd, 2023
- What are stem cells? Throw light on various types of stem cells and ... - Insights IAS - November 23rd, 2023
- The Paul G. Allen Family Foundation awards $10.5 million to new ... - EurekAlert - November 23rd, 2023
- Daily briefing: Why these PhD scientists went into teaching - Nature.com - November 23rd, 2023
- Innovative Therapy Targets Rare, Hereditary Diseases - Mirage News - November 23rd, 2023
- Scientists uncover "genomic tug of war" that influences ... - News-Medical.Net - November 21st, 2023
- DOT1L is a barrier to histone acetylation during reprogramming to ... - Science - November 21st, 2023
- Tumor microenvironment composition & related therapy in HCC | JHC - Dove Medical Press - November 21st, 2023
- T-Therapeutics raises $59M in series A for T-cell receptors - BioWorld Online - November 19th, 2023
Recent Comments